Zinc, its biological role and use in dermatology


Cite item

Full Text

Abstract

This literature review detines the biological role ot zinc in the human body, immune homeostasis and skin physiology as well as pathophysiology ot skin diseases. It describes the current range ot systemic and topical zinc preparations and their pharmacological characteristics. The review also describes skin diseases that may be treated with the use ot zinc preparations on a grounded basis, and discloses the clinical experience ot the use ot these drugs described in the world literature. It sets out certain recommendations tor using zinc preparations in clinical practice.

About the authors

A N KHLEBNIKOVA

I.M. Sechenov First Moscow State Medical University

д.м.н., профессор кафедры кожных и венерических болезней

D D PETRUNIN

Representative Office ot Astellas Pharma Europe B.V

к.м.н., медицинский советник

References

  1. Воскресенский П.А., Каверина А.А., Парменов К.Я. и др. Справочник по химии. Изд. 4-е, перераб. М: Просвещение, 1978; 287
  2. Raulin J. Etudes cliniques sur la vegetation. Ann Sci Nat Bot Biol Veg 1869; 11: 93
  3. Зеленин К.Н. Химия: учебник для медицинских вузов. СПб: Специальная литература, 1997; 688
  4. Brocard A., Dreno B. Innate immunity: a crucial target for zinc in the treatment of inflammatory dermatosis. J Eur Acad Dermatol Venerol 2011; 25: 1146—1152.
  5. U.S. National library of Medicine. Toxnet database. [WWW document] 2010. URL http://toxnet.nlm.nih.gov
  6. Coleman J. Zinc proteins: enzymes, storage proteins, transcription factors, and replication proteins. Annu Rev Biochem 1992; 61: 897—946.
  7. Prasad A.S. Discovery of human zinc deficiency: 50 years later. J Trace Elem Med 2012; 26(2—3): 66—9.
  8. Klug A. The discovery of zinc fingers and their development for practical applications in gene regulation and genome manipulation. Q Rev Biophys. 2010; 43(1): 1—21.
  9. Hernick M., Fierke C. Zinc hydrolases: the mechanisms of zinc-dependent deacetylases. Arch Biochem Biophys 2005; 433: 71—84.
  10. Berg J.M., Shi Y. The galvanization of biology: a growing appreciation for the roles of zinc. Science 1996; 271: 1081—5.
  11. Sternlicht M., Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463—516.
  12. Schwartz J.R., Marsh R.G., Draelos Z.D. Zinc and Skin Health: Overview of Physiology and Pharmacology. Dermatol Surg 2005; 31: 837—847.
  13. Kazimierczak W., Maslinski C. The mechanism of the inhibitory action of zinc on histamine release from mast cells by compound 48/80. Agents Actions 1974; 3/4: 203—4.
  14. Hogberg B., Uvnas B. Further observations on the disruption of rat mesentery mast cells caused by compound 48/80, antigen-antibody reaction, lecithin-ase A and decylamine. Acta Physiol Scand 1960; 48: 133—45.
  15. Marone G., Columo A., De Paulis R. et al. Physiological concentrations of zinc inhibit the release of histamine from human basophils and lung mast cells. Agents Actions 1986; 18: 103—6.
  16. Chvapil M. Effect of zinc on cells and biomembranes. Med Clin North Am 1976; 60: 799—812.
  17. Karl L., Chvapil M., Zukoski C. Effect of zinc on the viability and phagocytic capacity of peritoneal macrophages. Proc Soc Exp Biol Med 1973; 142: 1123—7.
  18. Wirth J., Fraker P., Kierszenbaum F. Zinc requirement for macrophage function: effect of zinc deficiency on uptake and killing of a protozoan parasite. Immunology 1989; 68: 114—9.
  19. Salvin S., Harecker B.L., Pan L.X. et al. The effect of dietary zinc and prothymosin alpha on cellular immune responses of RF-J mice. Clin Immunol Immunopathol 1987; 43: 281—8.
  20. Singh K., Zaldi S.I., Raisuddin S. et al. Effect of zinc on immune functions and host resistance against infection and tumor challenge. Immunopharmacol Immunotoxicol 1992; 14: 813—40.
  21. Weston W., Huff J.C., Humbert J.R. et al. Zinc correction of defective chemotaxis in acrodermatitis entero-pathica. Arch Dermatol 1977; 113: 422—5.
  22. Briggs W.A., Pederson M.M., Manajan S.K. et al. Lymphocyte and granulocyte function in zinc-treated and zinc-deficient hemodialysis patients. Kidney Int 1982; 21: 827—32.
  23. Fernandes G., Nair M., Onoe K. et al. Impairment of cell-mediated immunity functions by dietary zinc deficiency in mice. Proc Natl Acad Sci U S A 1979; 76: 457—61.
  24. Allen J., Perri R.T., McClain C.J. et al. Alterations in human natural killer cell activity and monocyte cytotoxicity induced by zinc deficiency. J Lab Clin Med 1983; 102: 577—89.
  25. Nagase H., Visse R., Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardio-vasc Res 2006; 69: 562—73.
  26. Lansdown A.B., Mirastschijski U., Stubbs N. et al. Zinc in wound healing: theoretical, experimental, and clinical aspects. Wound Repair Regen 2007; 15(1): 2—16.
  27. Gomis-Ruth F.X. Structural aspects of the metzincin clan of metalloendopeptidases. Mol Biotechnol 2003; 24: 157—202.
  28. Springman E.B., Nagase H., Birkedal-Hansen H., Van Wart H.E. Zinc content and function in human fibroblast collagenase. Biochemistry 1995; 34: 15713—20.
  29. Prasad A.S., Meftah S., Abdallah J. et al. Serum thymulin in human zinc deficiency. J Clin Invest 1988; 82: 1202—10.
  30. Moulder K., Steward M.W. Experimental zinc deficiency: effects on cellular responses and the affinity of humoral antibody. Clin Exp Immunol 1989; 77: 269—74.
  31. Cunningham-Rundles C., Cunningham-Rundles S., Iwata T. et al. Zinc deficiency, depressed thymic hormones, and T lymphocyte dysfunction in patients with hypogammaglobulinemia. Clin Immunol Immu-nopathol 1981; 21: 387—96.
  32. Cook-Mills J.M., Fraker P.J. Functional capacity of the residual lymphocytes in zinc deficient mice. Br J Nutr 1993; 69: 835-48.
  33. Salas M., Kirchner H. Induction of interferon-gamma in human leukocyte cultures stimulated by Zn2+. Clin Immunol Immunopathol 1987; 45: 139—42.
  34. Salgueiro M., Zubillaga M., Lysionek A et al. Zinc status and immune system relationship: a review. Biol Trace Elem Res 2000; 76: 193—205.
  35. Bao B., Prasad A.S., Beck FWJ, Bao G.W., Singh T., Ali S. et al. Intracellular free zinc up-regulates IFN-γ and T-bet essential for Th1 differentiation in Con-A stimulated HUT-78 cells. Biosci Biotechnol Res Commun 2011; 407: 703—7.
  36. Jarrousse V., Castex-Rizzi N., Khammari A. et al. Zinc salts inhibit in vitro Toll-like receptor 2 surface expression by keratinocytes. Eur J Dermatol 2007; 17(6): 492—6.
  37. Weller R. Nitric oxide—a newly discovered chemical transmitter in human skin. Br J Dermatol 1997; 137: 665—72.
  38. Yamaoka J., Kume T., Akaike A., Miyachi Y. Suppressive effect of zinc ion on iNOS expression induced by interferon-gamma or tumor necrosis factor-alpha in murine keratinocytes. J Dermatol Sci 2000; 23(1): 27—35.
  39. Abou-Mohamed G., Papapetropoulos A., Catravas J.D. et al. Zn2+ inhibits nitric oxide formation in response to lipopolysaccharides: implications in its anti-inflammatory activity. Eur J Pharmacol 1998; 341: 265—72.
  40. Guéniche A., Viac J., Lizard G. et al. Protective effect of zinc on keratinocyte activation markers induced by interferon or nickel. Acta Derm Venereol 1995; 75: 19—23.
  41. Bray T.M., Bettger W.J. The physiological role of zinc as an antioxidant. Free Radic Biol Med 1990; 8: 281—91.
  42. Rostan E., DeBuus H.V., Madey D.L. et al. Evidence supporting zinc as an important antioxidant for skin. Int J Dermatol 2002; 41: 606—11.
  43. Record I.R., Jannes M., Dreosti I.E. Protection by zinc against UVA and UVB-induced cellular and genomic damage in vivo and in vitro. Biol Trace Elem Res 1996; 53: 19—25.
  44. Richard M.J., Guiraud P., Leccia M.T. et al. Effect of zinc supplementation on resistance of cultured human skin fibroblasts toward oxidant stress. Biol Trace Elem Res 1993; 37: 187—99.
  45. Carraro C., Pathak M. Characterization of superoxide dismutase from mammalian skin epidermis. J Invest Dermatol 1988; 90: 31—6.
  46. Abel J., de Reuiter N. Inhibition of hydroxyl radicalgenerated DNA degradation by metallothionein. Toxicol Lett 1989; 47: 191—6.
  47. Soo C., Shaw W.W., Zhang X., Longaker M.T. et al. Differential expression of matrix metalloproteinases and their tissue-derived inhibitors in cutaneous wound repair. Plast Reconstr Surg 2000; 105: 638—47.
  48. Ravanti L., Kahari V.M. Matrix metalloproteinases in wound repair (review). Int J Mol Med 2000; 6: 391—407.
  49. Alpaslan G., Nakajima T., Takano Y. Extracellular alkaline phosphatase activity as a possible marker for wound healing: a preliminary report. J Oral Maxillofac Surg 1997; 55: 56—62.
  50. Tenaud I., Leroy S., Chebassier N., Dreno B. Zinc, copper and manganese enhanced keratinocyte migration through a functional modulation of keratino-cyte integrins. Exp Dermatol 2000; 9: 407—16.
  51. Iwata M., Takebayashi T., Ohta H., Alcalde R.E. et al. Zinc accumulation and metallothionein gene expression in the proliferating epidermis during wound healing in mouse skin. Histochem Cell Biol 1999; 112: 283—90.
  52. Lansdown ABG, Sampson B., Rowe A. Sequential changes in trace metal, metallothionein and calmodulin concentrations in healing skin wounds. J Anat 1999; 195 (Part 3): 375—86.
  53. Savlov E.D., Strain W.H., Huegin F. Radiozinc studies in experimental wound healing. J Surg Res 1962; 2: 209—12.
  54. Mirastschijski U., Haaksma C.J., Tomasek J.J., Agren M.S. Matrix metalloproteinase inhibitor GM 6001 attenuates keratinocyte migration, contraction and myofibroblast formation in skin wounds. Exp Cell Res 2004; 299: 465—75.
  55. Soderberg T., Agren M., Tengrup I., Hallmans G., Banck G. The effects of an occlusive zinc medicated dressing on the bacterial flora in excised wounds in the rat. Infection 1989; 17: 81—5.
  56. Fox C.L. Jr, Rao T.N., Azmeth R. et al. Comparative evaluation of zinc sulfadiazine and silver sulfadiazine in burn wound infection. J Burn Care Rehabil 1990; 11: 112—7.
  57. Bojar R., Eady E., Jones C. et al. Inhibition of erythromycin-resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc. Br J Dermatol 1994; 130: 329—36.
  58. Rebello T., Atherton D., Holden C. The effect of oral zinc administration on sebum free fatty acids in acne vulgaris. Acta Derm Venereol. 1986; 66: 305—10.
  59. Scrimshaw N.S., Young V.R. The requirements of human nutrition. Sci Am 1976; 235: 50—64.
  60. Fox SMR. The status of zinc in human nutrition. World Rev Nutr Diet 1970; 12: 208—26.
  61. Osis D., Kramer L., Wiatrowski E., Spencer H. Dietary zinc intake in man. Am J Clin Nutr 1972; 25: 582—8.
  62. Murphy E., Willis B., Watt B. Provisional tables on the zinc content of foods. J Am Diet Assoc 1975; 66: 345—55.
  63. Prasad A.S. Zinc: an overview. Nutrition 1995; 11: 93—9.
  64. King J.C., Shames D.M., Woodhouse L.R. Zinc homeostasis in humans. J Nutr 2000; 130: 1360S—6S.
  65. Krebs N.E., Hambidge K.M. Zinc metabolism and homeostasis: the application of tracer techniques to human zinc physiology. Biometals 2001; 14: 397—412.
  66. Sandstrom B. Bioavailability of zinc. Eur J Clin Nutr 1997; 51 (Suppl. 1): S17—9.
  67. Wastney M.E., Aamodt R.L., Rumble W.F., Henkin R.I. Kinetic analysis of zinc metabolism and its regulation in normal humans. Am J Physiol 1986; 251: R398—408.
  68. Vallee B.L., Falchuk K.H. The biochemical basis of zinc physiology. Physiol Rev 1993; 73: 79—118.
  69. Chimienti F., Aouffen M., Favier A., Seve M. Zinc homeostasis-regulating proteins: new drug targets for triggering cell fate. Curr Drug Targets 2003; 4: 323—38.
  70. Michaelsson G., Ljunghall K., Danielson B.G. Zinc in epidermis and dermis in healthy subjects. Acta Derm Venereol 1980; 60: 295—9.
  71. Molokhia M.M., Portnoy B. Neutron activation analysis of trace elements in skin. 3. Zinc in normal skin. Br J Dermatol 1969; 81: 759—62.
  72. Lansdown ABG. Calcium: a potential central regulator in wound healing in the skin. Wound Repair Regen 2002; 10: 271—85.
  73. Forslind B., Lindberg M., Roomans G.M., Pallon J., Werner-Linde Y. Aspects on the physiology of human skin: studies using particle probe analysis. Microsc Res Tech 1997; 38: 373—86.
  74. Heng M.K., Song M.K., Heng M.C. Reciprocity between tissue calmodulin and cAMP levels: modulation by excess zinc. Br J Dermatol 1993; 129: 280—5.
  75. Lengyel I., Fieuw-Makaroff S., Hall A.L. et al. Modulation of the phosphorylation and activity of calcium/calmodulin-dependent protein kinase II by zinc. J Neurochem 2000; 75: 594—605.
  76. Henkin R.I., Schecter P.J., Friedewald W.T. et al. A double blind study of the effects of zinc sulfate on taste and smell dysfunction. Am J Med Sci 1976; 272: 285—99.
  77. Gallo R.L., Dorschner R.A., Takashima S., et al. Endothelial cell surface alkaline phosphatase activity is induced by IL-6 released during wound repair. J Invest Dermatol 1997; 109: 597—603.
  78. Jones P.W., Williams D.R. The use and role of zinc and its compounds in wound healing. Met Ions Biol Syst 2004; 41: 139—83.
  79. Kury S., Dreno B., Bezieau S., Giraudet S. et al. Identification of SLC39A4, a gene involved in acrodermatitis enteropathica. Nat Genet 2002; 31: 239—40.
  80. Lansdown ABG. Interspecies variations in response to topical application of selected zinc compounds. Food Chem Toxicol 1991; 29: 57—64.
  81. Rosentul M.A., Розентул М.А. General therapy of skin diseases. М.,1952. [Общая терапия кожных болезней.М., 1952; 376.]
  82. Krasnoselskich T.V., Moshkalova I.A., Mikheev U.N. Basics topical treatment of skin diseases. Vasculitis of the skin. / Editor Ye.V. Sokolovsky. SPb: SO-TIS.1999. [Основы наружной терапии болезней кожи. Васкулиты кожи. Под ред. Е.В. Соколовского. СПб: Сотис, 1999; 189.]
  83. Sambandan D.R., Ratner D. Sunscreens: An overview and update. J Am Acad Dermatol 2011; 64: 748—58.
  84. Scribner M.D. Zinc sulfate and axillary perspiration odor. Arch Dermatol 1977; 113: 1302.
  85. Chairig A., Froebe C., Simone A. et al. Inhibitor of odor-producing axillary bacterial exoenzymes. J Soc Cosmet Chem 1991; 42: 133—45.
  86. Hostynek J.J. Factors determining percutaneous metal absorption. Food Chem Toxicol 2003; 41: 327—45.
  87. Pirot F., Millet J., Kalia Y.N., Humbert P. In vitro study of percutaneous absorption, cutaneous bioavailability and bioequivalence of zinc and copper from five topical formulations. Skin Pharmacol 1996; 9: 259—69.
  88. Agren M.S. Percutaneous absorption of zinc from zinc oxide applied topically to intact skin in man. Derma-tologica 1990; 180: 36—9.
  89. Grasso P., Lansdown ABG. Methods of measuring and factors affecting percutaneous absorption. Int J Cosmet Sci 1972; 23: 481—521.
  90. Scott A. The behaviour of radioactive mercury and zinc after application to normal and abnormal skin. Br J Dermatol 1959; 71: 181—9.
  91. Agren M.S. Influence of two vehicles for zinc oxide on zinc absorption through intact skin and wounds. Acta Derm Venereol 1991; 71: 153—6.
  92. Gamer A.O., Leibold E., van Ravenzwaay B. The in vitro absorption of microfine zinc oxide and titanium dioxide through porcine skin. Toxicol In Vitro 2006; 20: 301—7.
  93. Gorodetsky R., Andriessen A., Polyansky I., Vexler A. Measurement of breast skin viscoelasticity and a pilot study on the potential radioprotective effect of a zinc-based cream. J Wound Care 1999; 8: 514—8.
  94. Hallmans G. Absorption of topically applied zinc and changes in zinc metabolism during wound healing. An experimental and clinical investigation. Acta Derm Venereol Suppl (Stockh) 1978; 58: 1—36.
  95. Keen C.L., Hurley L.S. Zinc absorption through skin: correction of zinc deficiency in the rat. Am J Clin Nutr 1977; 30: 528—30.
  96. Gang R.K. Adhesive zinc tape in burns: results of a clinical trial. Burns 1980; 7: 322—5.
  97. Nitzan Y.B., Cohen A.D. Zinc in skin pathology and care. J Dermatol Treat 2006; 17: 205—210.
  98. Marks R., Pearse A.D., Walker A.P. The effects of a shampoo containing zinc pyrithione on the control of dandruff. Br J Dermatol 1985; 112: 415—22.
  99. Warner R.R., Schwartz J.R., Boissy Y. et al. Dandruff has an altered stratum corneum ultrastructure that is improved with zinc pyrithione shampoo. J Am Acad Dermatol 2001; 45: 897—903.
  100. Pittelkow M.R., Benson L.M., Naylor S., Tomlinson A.J. Detection of corticosteroid in an over-the-counter product. JAMA. 1998; 280: 327—328.
  101. Kupic I.F. FDA warns consumers not to use Skin Cap. HHS News: United States Department of Health and Human Services; 1997.
  102. FDA Import Alert 61-06: "Detention Without Physical Examination of Skin Cap Spray, Shampoo And Cream" 10/02/2009 http://www.accessdata.fda.gov/ cms_ia/importalert_165.html
  103. Swanson D.L., Pittelkow M.R., Benson L.M. et al. Deja Vu All Over Again: Skin Cap Still Contains a High-Potency Glucocorticosteroid. Arch Dermatol 2005; 141: 801—803.
  104. Prasad A., Halsted J., Nadimi M. Syndrome of iron deficiency anemia, hepatosplenomegaly, hypogonadism, dwarfism and geophagia. Am J Med. 1961; 31: 532—46.
  105. Brown M.A., Thom J.V., Orth G.L. et al. Food poisoning involving zinc contamination. Arch Environ Health 1964; 8: 657—660.
  106. Van Campen D.R. Copper interference with the intestinal absorption of zinc-65 by rats. J Nutr 1969; 97: 104—108.
  107. Myung S.J., Yang S.K., Jung H.Y. et al. Zinc deficiency manifested by dermatitis and visual dysfunction in a patient with Crohn’s disease. J Gastroenterol 1998; 33: 876—9.
  108. Narkewicz M.R., Krebs N., Karrer F. et al. Correction of hypozincemia following liver transplantation in children is associated with reduced urinary zinc loss. Hepatology 1999; 29: 830—3.
  109. Prasad A.S., Miale A. Jr, Farid Z. et al. Zinc metabolism in patients with the syndrome of iron deficiency anemia, hepatosplenomegaly, dwarfism, and hypog-nadism. J Lab Clin Med 1963; 61: 537—49.
  110. Dreno B., Trossaert M., Boiteau H.L. et al. Zinc salts effects on granulocyte zinc concentration and chemotaxis in acne patients. Acta Derm Venereol 1992; 72: 250—252.
  111. Danbolt N., Closs K. Akrodermatitis enteropathica. Acta Derm Venereol. 1942; 23: 127—69.
  112. Barnes P., Moynahan E. Zinc deficiency in acrodermatitis enteropathica: multiple dietary intolerance treated with synthetic diet. Proc R Soc Med 1973; 66: 327—9.
  113. Kury S., Dreno B., Bezieau S. et al. Identification of SLC39A4, a gene involved in acrodermatitis entero-pathica. Nat Genet. 2002; 31: 239—40.
  114. Moynahan E.J. Letter: acrodermatitis enteropathica: a lethal inherited human zinc-deficiency disorder. Lancet 1974; 2: 399—400.
  115. Braun O.H., Heilmann K., Pauli W. et al. Acrodermatitis enteropathica: recent findings concerning clinical features, pathogenesis, diagnosis and therapy. Eur J Pediatr 1976; 121: 247—61.
  116. Borroni G., Brazzelli V., Vignati G. et al. Bullous lesions in acrodermatitis enteropathica. Histopathologic findings regarding two patients. Am J Derma-topathol 1992; 14: 304—9.
  117. Sugimoto Y., Lopez-Solache I., Labrie F. et al. Cations inhibit specifically type I 5a-reductase found in human skin. J Invest Dermatol 1995; 104: 775—8.
  118. Stamatiadis D., Bulteau-Portois M.C., Mowszowicz L. Inhibition of 5a-reductase activity in human skin by zinc and azelaic acid. Br J Dermatol 1988; 119: 627—32.
  119. Fitzherbert J. Zinc deficiency in acne vulgaris. Med J Aust. 1977; 2(20): 685—6.
  120. Michaelsson G. Zinc therapy in acrodermatitis enteropathica. Acta Derm Venereol. 1974; 54: 377—81.
  121. Hillstrom L., Pettersson L., Hellbe L. et al. Comparison of oral treatment with zinc sulphate and placebo in acne vulgaris. Br J Dermatol. 1977; 97: 681—4.
  122. Goransson K., Liden S., Odsell L. Oral zinc in acne vulgaris: a clinical and methodological study. Acta Derm Venereol. 1978; 58: 443—8.
  123. Verma K., Saini A., Dhamija S. Oral zinc sulphate therapy in acne vulgaris: a double-blind trial. Acta Derm Venereol. 1980; 60: 337—40.
  124. Orris L., Shalita A., Sibulkin D. et al. Oral zinc therapy of acne. Absorption and clinical effect. Arch Dermatol. 1978; 114: 1018—20.
  125. Weimar V., Puhl S., Smith W., tenBroeke J. Zinc sulfate in acne vulgaris. Arch Dermatol. 1978; 114: 1776—8.
  126. Cunliffe W. Unacceptable side-effects of oral zinc sulphate in the treatment of acne vulgaris. Br J Dermatol. 1979;101:363.
  127. Meynadier J. Efficacy and safety study of two zinc gluconate regimens in the treatment of inflammatory acne. Eur J Dermatol 2000; 10: 269—273.
  128. Dreno B., Amblard P., Agache P., Sirot S., Litoux P. Low doses of zinc gluconate for inflammatory acne. Acta Derm Venereol Suppl (Stockh). 1989; 69: 541—3.
  129. Michaelsson G., Juhlin L., Ljunghall K. A doubleblind study of the effect of zinc and oxytetracycline in acne vulgaris. Br J Dermatol 1977; 97: 561—566.
  130. Revuz J, Amblard P., Dreno B. et al. Efficacite' du gluconate de zinc dans le traitement de l’acne' inflammatoire. Abstr Dermatol 1990; 77: 2—4.
  131. Cunliffe W.J., Burke B., Dodman B. et al. A doubleblind trial of a zinc sulphate/citrate complex and tetracycline in the treatment of acne vulgaris. Br J Dermatol 1979; 101: 321—325.
  132. Dreno B., Moyse D., Alirezai M. et al. Multicenter randomized comparative double-blind controlled clinical trial of the safety and efficacy of zinc gluconate versus minocycline hydrochloride in the treatment of inflammatory acne vulgaris. Dermatology 2001; 203: 135—140.
  133. Duteil L., Queille-Roussel C., Ortonne J.P. Assessment of the photosensitization potential of zinc gluconate. Ann Dermatol Venereol 2005; 132: 219—224.
  134. Dreno B., Blouin E. Acne, pregnant women and zinc salts: a literature review. Ann Dermatol Venereol 2008; 135: 27—33.
  135. Cochran R., Tucker S., Flannigan S. Topical zinc therapy for acne vulgaris. Int J Dermatol 1985; 24: 188—90.
  136. Illés J., Javor A., Szijartó E. Zinc-hyaluronate: ana original organotherapeutic compound of Gedeon Richter Ltd. Acta Pharm Hung. 2002; 72(1): 15—24.
  137. Instruction on medical application of a preparation of Zinerit. [Инструкция по медицинскому применению препарата Зинерит П №013569/01110309.]
  138. Dreno B., Foulc P., Reynaud A. et al. Effect of zinc gluconate on propionibacterium acnes resistance to erythromycin in patients with inflammatory acne: in vitro and in vivo study. Eur J Dermatol 2005; 15 (3): 152—5.
  139. Holland K.T., Bojar R.A., Cunliffe W.J. et al. The effect of zinc and erythromycin on the growth of erythromycin-resistant and erythromycin-sensitive isolates of Propionibacterium acnes: an in-vitro study. Br J Dermatol 1992; 126(5): 505—9.
  140. van Hoogdalem E.J., Terpstra I.J., Baven A.L. Evaluation of the effect of zinc acetate on the stratum corneum penetration kinetics of erythromycin in healthy male volunteers. Skin Pharmacol 1996; 9(2): 104—10.
  141. Strauss J.S., Stranieri A.M. Acne treatment with topical erythromycin and zinc: Effect on Propionibacterium acnes and free fatty acid composition. J Am Acad Dermatol 1984; 11(1): 86—89.
  142. Piérard-Franchimont C., Goffin V., Visser J.N. и соавт. A double-blind controlled evaluation of the sebosuppressive activity of topical erythromycin-zinc complex. Eur J Clin Pharmacol 1995; 49(1—2): 57—60.
  143. Schachner L., Pestana A., Kittles C. A clinical trial comparing the safety and efficacy of a topical eryth-romycin-zinc formulation with a topical clindamycin formulation. J Am Acad Dermatol. 1990; 22(3): 489—95.
  144. Habbema L., Koopmans B., Menke H.E. et al. A 4% erythromycin and zinc combination (Zineryt) versus 2% erythromycin (Eryderm) in acne vulgaris: a randomized, double-blind comparative study. Br J Dermatol. 1989; 121(4): 497—502.
  145. Chu A, Huber FJ, Plott RT. The comparative efficacy of benzoyl peroxide 5%/erythromycin 3% gel and erythromycin 4%/zinc 1.2% solution in the treatment of acne vulgaris. Br J Dermatol. 1997; 136(2): 235—8.
  146. Langner A., Sheehan-Dare R., Layton A. A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide (Duac) and erythromycin + zinc acetate (Zineryt) in the treatment of mild to moderate facial acne vulgaris. J Eur Acad Dermatol Venereol. 2007; 21(3): 311—9.
  147. Feucht C.L., Allen B.S., Chalker D.K., Smith J.G. Jr. Topical erythromycin with zinc in acne. A doubleblind controlled study. J Am Acad Dermatol. 1980; 3(5): 483—91.
  148. Stainforth J., MacDonald-Hull S., Papworth-Smith J.W. et al. Single-blind comparison of topical erythromycin/ zinc lotion and oral minocycline in the treatment of acne vulgaris. J Dermatol Treat 1993; 4: 119—122.
  149. Сергеев А.Ю., Бурцева Г.Н., Сергеев В.Ю. Фармакоэпидемиология акне и анонимная оценка лечения пациентами. Иммунопатология, аллергология, инфектология 2012; 4: 102—111
  150. Белькова Ю.А., Петрунин Д.Д. О местном применении антибактериальных препаратов в терапии акне. Вестник дерматологии и венерологии 2010; 3: 75—85
  151. Scheinfeld N. Diaper dermatitis. A review and brief survey of eruptions of the diaper area. Am J Clin Dermatol 2005; 6(5): 273—281.
  152. Collipp P.J., Kuo B., Castro-Magana M. et al. Hair zinc, scalp hair quality, and diaper rash in normal infants. Cutis 1985; 35: 66—70.
  153. Baldwin S., Odio M., Haines S. et al. Skin benefits from continuous topical administration of a zinc oxide/petrolatum formulation by a novel disposable diaper. J Eur Acad Dermatol Venereol. 2001; 15(suppl 1): 5—11.
  154. Arad A., Mimouni D., Ben-Amitai D. et al. Efficacy of topical application of eosin compared with zinc oxide paste and corticosteroid cream for diaper dermatitis. Dermatology. 1999; 199: 319—22.
  155. Imokawa G., Okamoto K. The inhibitory effect of zinc pyrithione on the epidermal proliferation of animal skins. Acta Derm Venereol. 1982; 62: 471—5.
  156. Gibson W., Hardy W., Groom M. The effect and mode of action of zinc pyrithione on cell growth. II. In vivo studies. Food Chem Toxicol. 1985; 23: 103—10.
  157. Schmidt A, Ruhl-Horster B. In vitro susceptibility of Malassezia furfur. Arzneimittelforschung. 1996; 46: 442—4.
  158. Rapaport M. A randomized, controlled clinical trial of four anti-dandruff shampoos. J Int Med Res. 1981; 9: 152—6.
  159. Pierard-Franchimont C., Goffin V., Decroix J., Pierard G. A multicenter randomized trial of keto-conazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic dermatitis. Skin Pharmacol Appl Skin Physiol. 2002; 15: 434—41.
  160. Sharquie K., Najim R., Farjou I., Al-Timimi D. Oral zinc sulphate in the treatment of acute cutaneous leishmaniasis. Clin Exp Dermatol. 2001; 26: 21—6.
  161. Firooz A., Khatami A., Khamesipour A. et al. Intra-lesional injection of 2% zinc sulfate solution in the treatment of acute old world cutaneous leishmaniasis: a randomized, doubleblind, controlled clinical trial. J Drugs Dermatol.2005; 4: 73—9.
  162. Iraji F., Vali A., Asilian A. et al. Comparison of intraiesionally injected zinc sulfate with meglumine antimoniate in the treatment of acute cutaneous leishmaniasis. Dermatology. 2004; 209: 46—9.
  163. Sharquie K., Najim R., Farjou I. A comparative controlled trial of intralesionally-administered zinc sulphate, hypertonic sodium chloride and pentavalent antimony compound against acute cutaneous leishmaniasis. Clin Exp Dermatol. 1997; 22: 169—73.
  164. Al-Gurairi F., Al-Waiz M., Sharquie K. Oral zinc sulphate in the treatment of recalcitrant viral warts: randomized placebocontrolled clinical trial. Br J Dermatol. 2002; 146: 423—31.
  165. Sadighha A. Oral zinc sulfate in recalcitrant multiple viral warts: a pilot study. J Eur Acad Dermatol Venereol 2009; 23: 715—6.
  166. Sharquie K.E., Khorsheed A.A., Al-Nuaimy A.A. Topical zinc sulfate solution for treatment of viral warts. Saudi Med J 2007; 28: 1418—21.
  167. Khattar J.A., Musharrafieh U.M., Tamim H. et al. Topical zinc oxide vs. salicylic acid-lactic acid combination in the treatment of warts. Int J Dermatol 2007; 46: 427—30.
  168. Rojas A., Phillips T. Patients with chronic leg ulcers show diminished levels of vitamins A and E, carotenes, and zinc. Dermatol Surg. 1999; 25: 601—4.
  169. Ackerman Z., Loewenthal E., Seidenbaum M. et al. Skin zinc concentrations in patients with varicose ulcers. Int J Dermatol. 1990; 29: 360—2.
  170. Brandrup F., Menne T., Agren M. et al. A randomized trial of two occlusive dressings in the treatment of leg ulcers. Acta Derm Venereol Suppl (Stockh). 1990; 70: 231—5.
  171. Stromberg H., Agren M. Topical zinc oxide treatment improves arterial and venous leg ulcers. Br J Dermatol. 1984; 111: 461—8.
  172. Agren M., Stromberg H. Topical treatment of pressure ulcers. A randomized comparative trial of Varidase and zinc oxide. Scand J Plast Reconstr Surg. 1985; 19: 97—100.
  173. Apelqvist J., Larsson J., Stenstrom A. Topical treatment of necrotic foot ulcers in diabetic patients: A comparative trial of DuoDerm and MeZinc. Br J Dermatol. 1990; 123: 787—92.
  174. Agren M. Studies on zinc in wound healing. Acta Derm Venereol Suppl (Stockh). 1990; 154: 1—36.
  175. Wilkinson E., Hawke C. Oral zinc for arterial and venous leg ulcers. Cochrane Database Syst Rev. 2000; 2(CD001273).
  176. Berger R., Fu J., Smiles K., et al. The effects of minoxidil, 1% pyrithione zinc and a combination of both on hair density: a randomized controlled trial. Br J Dermatol. 2003; 149: 354—62.
  177. Ead R. Oral zinc sulphate in alopacia areata — a double blind trial. Br J Dermatol. 1981; 104: 483—4.
  178. Rushton D. Nutritional factors and hair loss. Clin Exp Dermatol. 2002; 27: 396—404.
  179. Najim R.A., Sharquie K.E., Abu-Raghif A.R. Oxidative stress in patients with Behcet’s disease: I correlation with severity and clinical parameters. J Dermatol 2007; 34: 308—14.
  180. Sharquie K.E., Najim R.A., Al-Dori W.S. et al. Oral zinc sulfate in the treatment of Behcet’s disease: a double blind cross-over study. J Dermatol 2006; 33: 541—6.
  181. Sharquie K.E., Najim R.A., Al-Salman H.N. Oral zinc sulfate in the treatment of rosacea: a double-blind, placebo-controlled study. Int J Dermatol 2006; 45: 857—61.
  182. Brocard A., Knol A.C., Khammari A. et al. Hidradenitis suppurativa and zinc: a new therapeutic approach. A pilot study. Dermatology 2007; 214: 325—7.
  183. Abeck D., Korting H.C., Braun-Falco O. Folliculitis decalvans. Long-lasting response to combined therapy with fusidic acid and zinc. Acta Derm Venereol 1992; 72: 143—5.
  184. Nofal A.A., Nofal E., Attwa E. et al. Necrolytic acral erythema: a variant of necrolytic migratory erythema or a distinct entity? Int J Dermatol 2005; 44(11): 916—21.
  185. de Carvalho Fantini B., Matsumoto F.Y., Arnone M. et al. Necrolytic acral erythema successfully treated with oral zinc. Int J Dermatol 2008; 47(8): 872—3.
  186. Khanna V.J., Shieh S., Benjamin J. et al. Necrolytic acral erythema associated with hepatitis C: effective treatment with interferon alfa and zinc. Arch Dermatol 2000; 136: 755—7.
  187. Abdallah M.A., Hull C., Horn T.D. Necrolytic acral erythema: a patient from the United States successfully treated with oral zinc. Arch Dermatol 2005; 141: 85—7.
  188. Geria A.N., Holcomb K.Z., Scheinfeld N.S. Necro-lytic acral erythema: a review of the literature. Cutis 2009; 83: 309—14.
  189. Bolanca I., Bolanca Z., Kuna K. et al. Chloasma—the mask of pregnancy [review]. Coll Antropol 2008; 32(Suppl 2): 139—41.
  190. Sharquie K.E., Al-Mashhadani S.A., Salman H.A. Topical 10% zinc sulfate solution for treatment of melasma. Dermatol Surg 2008; 34: 1346—9.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 KHLEBNIKOVA A.N., PETRUNIN D.D.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».